Evidence map›Paper›PMID 40213350›Full record

ArticleProstate international2025

Assessing the influence of prostate tissue traits on Gallium-68 prostate-specific membrane-antigen positron-emission tomography/computed tomography: predictive factors for image positivity and locoregional recurrence in prostate cancer patients treated with radical prostatectomy and without prior or salvage treatment.

Cristina Gutiérrez Castañé, José E Robles García, Jorge M Núñez-Córdoba, Andrés Calva López, Vanessa Talavera Cobo, Carmina A Muñoz Bastidas, Juan Colombas Vives, Francisco J Ancizu Marckert, Bernardino Miñana López

Abstract read
In one paragraph

Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cristina Gutiérrez CastañéDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
José E Robles GarcíaDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Jorge M Núñez-CórdobaResearch Support Service, Central Clinical Trials Unit, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Andrés Calva LópezDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Vanessa Talavera CoboDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Carmina A Muñoz BastidasDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Juan Colombas VivesDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Francisco J Ancizu MarckertDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Bernardino Miñana LópezDepartment of Urology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gallium-68 prostate-specific membrane-antigen positron emission tomography/computed tomography ( Methods: We conducted a retrospective analysis of 230 prostate cancer patients treated with RP and without prior salvage or adjuvant radiotherapy or systemic treatments. All patients underwent Results: Our analysis showed that Conclusion: Pathological findings emerge as robust predictors of

Indexed as

Gallium RadioisotopesLocalNeoplasm RecurrencePositron-Emission TomographyProstate-Specific Membrane Antigen (PSMA)Prostatic Neoplasms

Identifiers

PMID40213350
PMCPMC11979366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.